Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Apixaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 20/20 | 0.98 |
| ▸ | F2 | P00734 | 5/20 | 0.98 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Apixaban SCHEMBL15534161 | 1.00 | F10 (0.98) | F10F2SLC29A1 | |
| Apixaban SCHEMBL118023 | 0.99 | F10 (1.00) | F10F2SLC29A1 | |
| SCHEMBL19086463 | 0.98 | F10 (0.98) | F10F2SLC29A1 | |
| Apixaban SCHEMBL14672486 | 0.98 | F10 (0.98) | F10F2SLC29A1 | |
| SCHEMBL16730331 | 0.96 | F10 (0.94) | F10F2SLC29A1 | |
| Apixaban SCHEMBL28348493 | 0.95 | F10 (0.93) | F10F2SLC29A1 | |
| Apixaban SCHEMBL19991448 | 0.95 | F10 (0.93) | F10F2SLC29A1 | |
| Apixaban SCHEMBL13321443 | 0.94 | F10 (0.91) | F10F2SLC29A1 | |
| Apixaban SCHEMBL22581184 | 0.94 | F10 (0.90) | F10F2SLC29A1 | |
| Apixaban SCHEMBL31267125 | 0.93 | F10 (0.88) | F10F2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3228619-B1 | PROCESS FOR THE PREPARATION OF APIXABAN | ZAKL FARMACEUTYCZNE POLPHARMA SA (PL) | 2020-07-29 | — | — | EP | claimed |
| EP-3228619-A1 | PROCESS FOR THE PREPARATION OF A APIXABAM | Zaklady Farmaceutyczne Polpharma SA (PL) | 2017-10-11 | — | — | EP | claimed |
| CN-111377915-B | Pyrazolo-pyridone compound crystal form D | 鲁南制药集团股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-3228619-B1 | PROCESS FOR THE PREPARATION OF APIXABAN | ZAKL FARMACEUTYCZNE POLPHARMA SA (PL) | 2020-07-29 | — | — | EP | disclosed |
| CN-111377915-A | Pyrazolo-pyridone compound crystal form D | 山东新时代药业有限公司 | 2020-07-07 | — | — | CN | disclosed |
| EP-3228619-A1 | PROCESS FOR THE PREPARATION OF A APIXABAM | Zaklady Farmaceutyczne Polpharma SA (PL) | 2017-10-11 | — | — | EP | disclosed |
| CN-104086544-A | Apixaban monohydrate as well as preparation method and medicinal composition thereof | SHANGHAI YOUSHOU PHARMACEUTICAL TECHNOLOGY DEV CO LTD | 2014-10-08 | — | — | CN | disclosed |
| CN-104086544-A | Apixaban monohydrate as well as preparation method and medicinal composition thereof | SHANGHAI YOUSHOU PHARMACEUTICAL TECHNOLOGY DEV CO LTD | 2014-10-08 | — | — | CN | disclosed |
| EP-2752414-A1 | Crystalline form of apixaban | Sandoz AG (CH) | 2014-07-09 | — | — | EP | disclosed |
| US-20070203178-A1 | CRYSTALLINE SOLVATES OF APIXABAN | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-30 | — | — | US | disclosed |
| US-20070203178-A1 | CRYSTALLINE SOLVATES OF APIXABAN | BRISTOL-MYERS SQUIBB COMPANY | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203178-A1 | CRYSTALLINE SOLVATES OF APIXABAN | AFF2, API5, F2 | F10 5/4885F2 3/4885SLC29A1 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.